← Leaderboards
Maria V. Barbolina
University Of Illinois At Chicago
$1,731,372
Attributed
$2,714,178
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $665.2K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,714,178 · 3
By mechanism
R01$1,965,612 · 1
R21$748,566 · 2
Top collaborators
- Peter Penzes3 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPharmaceutical PreparationsProteinsMolecularPublishingPre-Clinical ModelSignal TransductionCellsPathway InteractionsMouse ModelPlayPhenotypeAffectPreventEpithelialOvarian CarcinomaChemotherapyNeoplasm MetastasisMalignant NeoplasmsCause Of DeathClinicCell Culture TechniquesBaseMalignant Epithelial Cell
Grant awards (7)
Rac-GEF signaling in dendritic spines$650,204
R01 · FY2025 · MH
Rac-GEF signaling in dendritic spines$650,204
R01 · FY2024 · MH
Rac-GEF signaling in dendritic spines$665,204
R01 · FY2023 · MH
Targeting Microtubule Associated Protein Tau in Ovarian Carcinoma to Increase Efficacy of Paclitaxel$173,891
R21 · FY2020 · CA · contact PI
Targeting Microtubule Associated Protein Tau in Ovarian Carcinoma to Increase Efficacy of Paclitaxel$203,458
R21 · FY2019 · CA · contact PI
Role of the Fractalkine Signaling in EOC$168,249
R21 · FY2012 · CA · contact PI
Role of the Fractalkine Signaling in EOC$202,968
R21 · FY2011 · CA · contact PI